Updated expert opinion guidelines regarding the effects of immunosuppressive agents on patch testing
- PMID: 39909349
- DOI: 10.1016/j.jaad.2025.01.078
Updated expert opinion guidelines regarding the effects of immunosuppressive agents on patch testing
Keywords: allergic contact dermatitis; biologics; immunosuppression; patch testing.
Conflict of interest statement
Conflicts of interest Dr Adler has served as a research investigator and/or scientific advisor to Abbvie and Dermavant. Dr Atwater received the Pfizer Independent Grant for Learning & Change and has consulted for Henkel. She is the director of the American Contact Dermatitis Society Contact Allergen Management Program (CAMP). Dr Botto is co-founder of Vetted Dermlab, a skincare company. Dr DeKoven has been on advisory boards for Abbvie and Leo pharmaceuticals. Dr DeLeo has consulted for Estee Lauder Industries. Dr Dunnick is a speaker for Pfizer. Dr Taylor has consulted for Johnson & Johnson, Bayer, Kao Brands, and Equinox Group; received royalties from Decision Support in Medicine; and owns noncontrolling shares of common stock in AstraZeneca, Cigna, Johnson & Johnson, Merck, and Opko Health. A nondependent child is an employee of Pfizer. He is a member of the Steering Committee of the Cosmetic Ingredient Review. Dr Yu has served as a consultant/advisory board/investigator for the following: Abbvie, Arcutis, Astria, Dermavant, iRhythm, Leo, Lilly, National Eczema Association, O'Glacee, Pfizer, Sanofi, Smartpractice, and Sol-Gel. He also receives honorarium from UptoDate. Author Sandler and Drs Belsito, Fowler Jr., Houle, Maibach, Mowad, Reeder, Warshaw, Wu, and Zippin have no conflicts of interest to declare.
LinkOut - more resources
Full Text Sources